Glimeto-PM1 Tablets

Composition

• Metformin Hydrochloride (Sustained Release) – 500 mg
• Glimepiride – 1 mg
• Pioglitazone – 15 mg

---

Mechanism of Action

Metformin Hydrochloride (SR) reduces hepatic glucose production, improves insulin sensitivity, and enhances peripheral glucose uptake. Its sustained-release formulation ensures gradual drug release, providing prolonged glycemic control with improved gastrointestinal tolerability.

Glimepiride stimulates insulin secretion from pancreatic beta cells, helping to lower blood glucose levels effectively.

Pioglitazone improves insulin sensitivity in muscle and adipose tissues by acting on PPAR-gamma receptors, thereby enhancing glucose utilization and reducing insulin resistance.

---

Key Benefits

• Triple-action mechanism for effective glycemic control
• Improves insulin sensitivity and glucose utilization
• Helps reduce fasting and postprandial blood glucose levels
• Supports reduction in HbA1c
• Sustained-release formulation for prolonged action
• Suitable for patients requiring combination therapy

---

Indications

• Type 2 Diabetes Mellitus
• Patients inadequately controlled on dual therapy
• Advanced combination therapy for improved glycemic management

---

Dosage & Administration

• To be taken as directed by the physician
• Usually taken with meals
• Tablets should be swallowed whole and not crushed or chewed

---

Precautions

• Risk of hypoglycemia due to sulfonylurea component
• Monitor for weight gain or fluid retention (pioglitazone)
• Use cautiously in patients with cardiac, renal, or hepatic conditions
• Regular monitoring of blood glucose is recommended
• Avoid excessive alcohol intake

---

Contraindications

• Type 1 Diabetes Mellitus
• Diabetic ketoacidosis
• Severe heart failure
• Severe renal or hepatic impairment
• Known hypersensitivity to any component

---

Storage

• Store in a cool and dry place below 25°C
• Protect from light and moisture
• Keep out of reach of children

---

Packaging

• 10 x 15 Tablets